BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Sarcomas AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Prognosis
207 results:

  • 1. Vitexicarpin Induces Apoptosis and Inhibits Metastatic Properties via the akt-PRAS40 Pathway in Human Osteosarcoma.
    Yun HM; Kwon HS; Lee JY; Park KR
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612399
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. USP3 promotes osteosarcoma progression via deubiquitinating EPHA2 and activating the PI3K/akt signaling pathway.
    Li A; Wang S; Nie J; Xiao S; Xie X; Zhang Y; Tong W; Yao G; Liu N; Dan F; Shu Z; Liu J; Liu Z; Yang F
    Cell Death Dis; 2024 Mar; 15(3):235. PubMed ID: 38531846
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Screening for Synergistic Reagents With Pazopanib Against Osteosarcoma Using a Compound Library.
    Yada Y; Asanuma K; Kakimto T; Okuno K; Okamoto T; Iino T; Nakamura T; Sudo A
    Anticancer Res; 2024 Mar; 44(3):1071-1078. PubMed ID: 38423639
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.
    Wang Y; Ma X; Xu E; Huang Z; Yang C; Zhu K; Dong Y; Zhang C
    Clin Transl Med; 2024 Feb; 14(2):e1586. PubMed ID: 38372422
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. LncRNA RPARP-AS1 promotes the progression of osteosarcoma cells through regulating lipid metabolism.
    Cai F; Liu L; Bo Y; Yan W; Tao X; Peng Y; Zhang Z; Liao Q; Yi Y
    BMC Cancer; 2024 Feb; 24(1):166. PubMed ID: 38308235
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Role of PAX6, TRPA1, BCL11B, MCOLN2, CUX1, EMX1 in colorectal cancer and osteosarcoma.
    Zhang J; Gao Q; Hou S; Chi X; Zheng M; Zhang Q; Shan H; Zhang X; Kang C
    Medicine (Baltimore); 2024 Feb; 103(5):e37056. PubMed ID: 38306561
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A study protocol for an open-label, single-arm, single-center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma.
    Huang H; Zhang H; Cao B
    Thorac Cancer; 2024 Feb; 15(5):427-433. PubMed ID: 38211967
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Predicting prognosis and immune status in sarcomas by identifying necroptosis-related lncRNAs.
    Wang Z; He A; Lu Z; Xu W; Wu G; Peng T
    Aging (Albany NY); 2024 Jan; 16(1):493-517. PubMed ID: 38194709
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
    Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
    Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Solute carrier family 35 member A2 regulates mitophagy through the PI3K/akt/mTOR axis, promoting the proliferation, migration, and invasion of osteosarcoma cells.
    Luo X; Zhang J; Guo C; Jiang N; Zhang F; Jiao Q; Xu K; Yang J; Qu G; Lv XB; Zhang Z
    Gene; 2024 Mar; 898():148110. PubMed ID: 38151177
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database.
    Mochizuki T; Ikegami M; Akiyama T
    Cancer Sci; 2024 Feb; 115(2):575-588. PubMed ID: 38115234
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. KLK10 promotes the progression of KRAS mutant colorectal cancer via PAR1-PDK1-akt signaling pathway.
    Wu K; Wu B; Yan K; Ding Q; Miao Z
    Cell Biol Int; 2024 Apr; 48(4):440-449. PubMed ID: 38115179
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Exploration in the Mechanism of Ginsenoside Rg5 for the Treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.
    Liu MY; Jiang DX; Zhao X; Zhang L; Zhang Y; Liu ZD; Liu RZ; Li HJ; Rong XY; Gao YZ
    Orthop Surg; 2024 Feb; 16(2):462-470. PubMed ID: 38086608
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. New emerging targets in osteosarcoma therapy: PTEN and PI3K/akt crosstalk in carcinogenesis.
    Sadrkhanloo M; Paskeh MDA; Hashemi M; Raesi R; Bahonar A; Nakhaee Z; Entezari M; Beig Goharrizi MAS; Salimimoghadam S; Ren J; Nabavi N; Rashidi M; Dehkhoda F; Taheriazam A; Tan SC; Hushmandi K
    Pathol Res Pract; 2023 Nov; 251():154902. PubMed ID: 37922723
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the akt pathway.
    Chen J; Xu Q; Liu D; Li X; Guo M; Chen X; Liao J; Lei R; Li W; Huang H; Saw PE; Song E; Yan X; Nie Y
    Cancer Commun (Lond); 2023 Nov; 43(11):1244-1266. PubMed ID: 37856423
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/akt/mTOR pathway.
    Wei Z; Xia K; Zheng D; Gong C; Guo W
    Mol Med; 2023 Oct; 29(1):133. PubMed ID: 37789274
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets.
    Bremmer F; Pongratanakul P; Skowron M; Che Y; Richter A; Küffer S; Reuter-Jessen K; Bohnenberger H; Pauls S; Kresbach C; Schüller U; Stühler K; Ströbel P; Albers P; Nettersheim D
    Br J Cancer; 2023 Nov; 129(10):1580-1589. PubMed ID: 37726478
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The Targeted Therapies for Osteosarcoma
    Wang S; Ren Q; Li G; Zhao X; Zhao X; Zhang Z
    Curr Mol Pharmacol; 2024; 17(1):e210823220109. PubMed ID: 37602543
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. METTL16 promotes osteosarcoma progression by downregulating VPS33B in an m
    Cheng J; Xu Z; Tan W; He J; Pan B; Zhang Y; Deng Y
    J Cell Physiol; 2024 Mar; 239(3):e31068. PubMed ID: 37357526
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/akt pathway in neighboring cells.
    Mancarella C; Giusti V; Caldoni G; Laginestra MA; Parra A; Toracchio L; Giordano G; Roncuzzi L; Piazzi M; Blalock W; Columbaro M; De Feo A; Scotlandi K
    Cancer Gene Ther; 2023 Sep; 30(9):1285-1295. PubMed ID: 37353558
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 11.